(Total Views: 410)
Posted On: 02/25/2021 6:22:36 PM
Post# of 154023
Dvb wrote:
Calstang -- what PR is that???
(regarding GSX meeting PE only for covid patients over 70 years old)
My response:
Link is below, The company is GSK.
BTW: They did a 60 Day Look at mortality, and for SOC it was 40% died!
This was a Phase II Clinical Trial....
35% Reduction in death rate for otilimab by GSK @ 60 days.
Maybe FDA is looking at 42 days or even 60 days for LL and Placebo deaths?
In those aged 70 years and above, 65.1% of those were alive and free of respiratory failure 28 days after treatment with otilimab plus standard of care, compared to 45.9% of patients with standard of care alone. (delta of 19.1%, 95% CI=5.2%, 33.1%) (nominal p-value=0.009).
In a mortality analysis up to day 60, the treatment difference was 14.4%. The rates were 40.4% for standard of care compared to 26% on otilimab plus standard of care (95% CI= 0.9%, 27.9%) (nominal p-value=0.040).
https://seekingalpha.com/news/3666606-gsks-co...king_alpha
Calstang -- what PR is that???
(regarding GSX meeting PE only for covid patients over 70 years old)
My response:
Link is below, The company is GSK.
BTW: They did a 60 Day Look at mortality, and for SOC it was 40% died!
This was a Phase II Clinical Trial....
35% Reduction in death rate for otilimab by GSK @ 60 days.
Maybe FDA is looking at 42 days or even 60 days for LL and Placebo deaths?
In those aged 70 years and above, 65.1% of those were alive and free of respiratory failure 28 days after treatment with otilimab plus standard of care, compared to 45.9% of patients with standard of care alone. (delta of 19.1%, 95% CI=5.2%, 33.1%) (nominal p-value=0.009).
In a mortality analysis up to day 60, the treatment difference was 14.4%. The rates were 40.4% for standard of care compared to 26% on otilimab plus standard of care (95% CI= 0.9%, 27.9%) (nominal p-value=0.040).
https://seekingalpha.com/news/3666606-gsks-co...king_alpha
(0)
(0)
